Pneumovax 23 dose concerns
The Therapeutic Goods Administration (TGA) is advising health professionals not to routinely give immunocompetent patients a second dose of Pneumovax 23 due to the risk of local injections site reactions.
As published in Australian Prescriber’s Medicines Safety Update, the TGA made the recommendation following a review of an apparent increased rate of injection site reactions following revaccination with Pneumovax 23.
The advice differs from current recommendations in the Australian Immunisation Handbook, which advise routine revaccination five years after the first dose.
However, revaccination should be considered for patients at high risk of serious pneumococcal disease, provided that at least five years have passed since the previous dose of Pneumovax 23.
TGA warning on atomoxetine
Health professionals have been warned about the...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.